Biological Therapies in Inflammatory Myopathies

Abd El Haleem Natour, Shaye Kivity*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Idiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement. Management of IIMs necessitates glucocorticoid therapy followed by conventional steroid-sparing agents to control disease activity. In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-line therapies are needed to minimize disease burden, avoid end-organ damage and steroid toxicity, and decrease mortality. These therapies may include biological disease-modifying antirheumatic drugs (bDMARDs), and to a lesser extent, targeted synthetic disease-modifying antirheumatic drugs (TSD). This article reviews the current use of bDMARDs, e.g. intravenous immuno-globulin and rituximab, and a TSD-Janus kinase inhibitors (JAKI)-along with their indications, efficacy, and safety in managing IIM.

Original languageEnglish
Article numbere0008
JournalRambam Maimonides Medical Journal
Issue number2
StatePublished - Apr 2023
Externally publishedYes


  • Abatacept
  • IVIg
  • JAKI
  • bDMARDs
  • idiopathic inflammatory myopathies
  • rituximab


Dive into the research topics of 'Biological Therapies in Inflammatory Myopathies'. Together they form a unique fingerprint.

Cite this